- Home
- RSLS vs SCNI Comparison
RSLS vs SCNI Comparison
Compare RSLS & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- SCNI
- Stock Information
- Founded
- RSLS 2002
- SCNI 2003
- Country
- RSLS United States
- SCNI Israel
- Employees
- RSLS N/A
- SCNI N/A
- Industry
- RSLS Medical/Dental Instruments
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RSLS Health Care
- SCNI Health Care
- Exchange
- RSLS Nasdaq
- SCNI Nasdaq
- Market Cap
- RSLS 3.1M
- SCNI 3.5M
- IPO Year
- RSLS 2007
- SCNI N/A
- Fundamental
- Price
- RSLS $4.38
- SCNI $3.40
- Analyst Decision
- RSLS Hold
- SCNI
- Analyst Count
- RSLS 1
- SCNI 0
- Target Price
- RSLS N/A
- SCNI N/A
- AVG Volume (30 Days)
- RSLS 30.3K
- SCNI 11.8K
- Earning Date
- RSLS 11-14-2024
- SCNI 11-22-2024
- Dividend Yield
- RSLS N/A
- SCNI N/A
- EPS Growth
- RSLS N/A
- SCNI N/A
- EPS
- RSLS N/A
- SCNI 8.20
- Revenue
- RSLS $8,183,000.00
- SCNI $452,000.00
- Revenue This Year
- RSLS $17.47
- SCNI N/A
- Revenue Next Year
- RSLS $20.00
- SCNI N/A
- P/E Ratio
- RSLS N/A
- SCNI $0.41
- Revenue Growth
- RSLS N/A
- SCNI N/A
- 52 Week Low
- RSLS $4.09
- SCNI $2.23
- 52 Week High
- RSLS $29.00
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- RSLS 32.94
- SCNI 51.71
- Support Level
- RSLS $4.09
- SCNI $3.20
- Resistance Level
- RSLS $4.80
- SCNI $3.55
- Average True Range (ATR)
- RSLS 0.40
- SCNI 0.17
- MACD
- RSLS -0.06
- SCNI 0.01
- Stochastic Oscillator
- RSLS 18.24
- SCNI 57.14
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.